AIV Logo AIV Assistant

Loading...

Logo Q32 Bio Inc. - QTTB Open Q32 Bio Inc. in new tab

2.26 USD
EPS
-4.34
P/B
-2.80
ROE
-491.67
Target Price
12.00 USD

2.2600 USD

2.260 USD

Daily: +0.00%
Key Metrics

Earnings date: May 6, 2026

EPS: -4.34

Book Value: -1.00

Price to Book: -2.80

% Insiders: 6.541%

Estimates

Forward P/E: -0.52

Forward EPS: -5.36

Target Mean Price: 12.00

DCF Valuation

Tweak assumptions to recompute fair value for Q32 Bio Inc. (QTTB)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Logo About Q32 Bio Inc. - (QTTB)

Sector: Healthcare

Website: https://www.q32bio.com

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.

Exchange Ticker
NASDAQ QTTB

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
March 26, 2024 0.060000
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion